Literature DB >> 15105388

Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: case report.

Erkut Attar1, Sinan Berkman, Samet Topuz, Bulent Baysal, Suleyman Akhan, Joseph T Chambers.   

Abstract

A young nulliparous woman with stage IIIC bilateral borderline micro-papillary serous carcinoma (MPSC) of the ovary underwent conservative surgery with optimal preservation of future fertility. The left ovary and a substantial portion of the right ovary were removed. The patient became pregnant at the first IVF cycle attempted after conservative management. A Cesarean section was performed in the 37th week of pregnancy and combined with very precise exploration; there were multiple non-invasive implants on the peritoneal surface and liver, and contra-lateral ovarian tissue was of normal appearance. Abdominal hysterectomy and right oophorectomy were done as a definitive treatment 3 months after the Caesarean section. The patient showed a rapid progression to invasive ovarian carcinoma in this period of time. MPSC has the greatest risk of malignant transformation among the advanced stage serous borderline tumours. Fertility-sparing surgery is an option for young, childless women who would like to preserve their fertility. However, the treatment must be taken very cautiously and requires rigorous surveillance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105388     DOI: 10.1093/humrep/deh226

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  2 in total

1.  Outcomes of fertility-sparing surgery for stage II and III serous borderline ovarian tumors.

Authors:  Ziyang Lu; Bin Li; Chao Gu
Journal:  J Int Med Res       Date:  2019-08-21       Impact factor: 1.671

2.  Outcomes of controlled ovarian hyperstimulation/in vitro fertilization for infertile patients with borderline ovarian tumor after conservative treatment.

Authors:  Chan Woo Park; Kwang Moon Yang; Hye Ok Kim; Sung Ran Hong; Tae Jin Kim; Kyung Taek Lim; Ki Heon Lee; Inn Soo Kang
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.